MSF Responds to new WHO guidance recommending vastly shorter, improved and better tolerated treatment for multi drug-resistant TB
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla
2-26 | Médecins Sans Frontières (MSF)'s statement on the escalating situation in Ukraine.
2-17 | CAPE TOWN - A vaccination support programme developed by MSF in Khayelitsha, South Africa, in partnership with the Western Cape Department of Health (WCDoH), has shown that it is possible to target and protect individuals with comorbidities that increase the risk of severe disease and death from COVID-19.
Trial of multidrug-resistant TB treatment ends enrolment early after independent board indicates new regimen is superior
3-24 | A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more patient data was extremely unlikely to change the trial’s outcome.
Johnson & Johnson TB drug price reduction is important step, and governments need to urgently scale up better treatment
7-6 | 120,707 people signed petitions urging the corporation to drop the price.